

Cholamandalam Investment and Finance Company Limited

February 20, 2026

Facilities/Instruments	Amount (₹ crore)	Rating ¹	Rating Action
Subordinated debt - IV	300.00	CARE AA+; Stable	Reaffirmed
Subordinated debt - V	700.00	CARE AA+; Stable	Reaffirmed
Subordinated debt - VI	1,500.00	CARE AA+; Stable	Reaffirmed
Perpetual debt instruments	300.00	CARE AA; Stable	Reaffirmed
Non-convertible debentures – I	1,000.00	CARE AA+; Stable	Reaffirmed
Non-convertible debentures - II	10,000.00	CARE AA+; Stable	Reaffirmed
Commercial paper	25,000.00 (Enhanced from 15,000.00)	CARE A1+	Reaffirmed
Subordinated debt – VII	2,000.00	CARE AA+; Stable	Assigned

Details of instruments/facilities in Annexure-1.

Rationale and key rating drivers

Ratings assigned to debt instruments of Cholamandalam Investment and Finance Company Limited (CIFCL) continue to factor in benefits derived from it being part of the Murugappa group and CIFCL's established track record in the vehicle finance (VF) segment, supported by a pan-India branch network, and experienced management team. Ratings derive strength from diversified funding profile, geographically diversified product portfolio, healthy profitability, and strong liquidity profile. Notably, the company's assets under management (AUM) have shown consistent growth of 27% from ₹145,646 crore as on March 31, 2024, to ₹184,746 crore as on March 31, 2025, and further to ₹210,704 crore as on December 31, 2025. Going forward, CARE Ratings Limited (CareEdge Ratings) expects sustained growth in the scale of operations.

However, ratings remain constrained considering the company's moderate asset quality metrics and moderately high gearing levels despite capital raise in FY24. Gross Stage 3 (GS3) and Net Stage 3 (NS3) assets stood at 2.81% and 1.54%, respectively, as on March 31, 2025, against 2.48% and 1.33%, respectively, as on March 31, 2024. As on December 31, 2025, GS3 and NS3 rose to 3.36% and 1.91%, respectively, primarily driven by the early arrival of monsoon, which disrupted vehicle movement in 9MFY26 and led to reduced utilisation. CARE Ratings Limited (CareEdge Ratings) notes that the company has enhanced the collection efforts which is expected to maintain the asset quality at broadly stable levels in the medium term.

Rating sensitivities: Factors likely to lead to rating actions

Positive factors: Factors that could individually or collectively lead to positive rating action/upgrade:

- Improvement in the scale of operations along with improvement in the profitability indicators, with a return on total assets (ROTA) of more than 3% on a sustained basis.
- Improvement in the capital structure.
- Improvement in the asset quality on a sustained basis.

Negative factors: Factors that could individually or collectively lead to negative rating action/downgrade:

- Deterioration of the asset quality parameters with an increase in gross non-performing assets (GNPA) beyond 5% on a sustained basis.
- Weakening of the capital adequacy levels, with Tier-I capital adequacy ratio (CAR) below 12% on a sustained basis.

¹Complete definition of ratings assigned are available at www.careratings.com and other CARE Ratings Limited's publications.

Analytical approach:

Standalone

Outlook: Stable

The stable outlook reflects likely continuation of stable credit profile, supported by a diversified product profile, healthy profitability and demonstrated fund-raising ability from diversified sources, including benefits derived from being part of the Murugappa group.

Detailed description of key rating drivers:

Key strengths

Benefits derived from being part of Murugappa group

CIFCL is a part of the Murugappa group, one of India's largest conglomerates founded in 1900, with a focus towards engineering, auto components, cycles, abrasives, sugar, farm inputs, fertilisers, plantations, bio-products, finance, general insurance, and nutraceuticals. The group has 29 businesses, including 10 companies listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).

Headquartered in Chennai, major companies of the group include Tube Investments of India Limited, Carborundum Universal Limited, Coromandel International Limited, CG Power and Industrial Solutions Limited, and E.I.D. Parry (India) Limited (rated 'CARE A1+'). Being part of the Murugappa group, CIFCL enjoys benefits through its vast client base, which provides comfort to the company's business growth profile. The company also derives financial support from the group, when required to support the business, as exhibited in the past. As on December 31, 2025, the promoter and promoter group hold 49.72% in the company. Over the years, CIFCL's size and absolute profits have improved. Its profit after tax (PAT) increased from ₹1,186 crore in FY19 to ₹4,259 crore in FY25. In 9MFY26, the company reported a PAT of ₹3,579 crore on total income of ₹22,906 crore compared to PAT of ₹2,992 on total income of ₹18,934 crore in 9MFY25. At present, CIFCL is a major contributor of profits and market capitalisation of the Murugappa group.

Growing scale of operations

CIFCL reported a 14% year-on-year (y-o-y) growth in total disbursements, increasing from ₹88,725 crore in FY24 to ₹100,869 crore in FY25. The company's business AUM grew by 27% in FY25, rising from ₹148,167 crore as on March 31, 2024, to ₹188,157 crore as on March 31, 2025. Disbursements for 9MFY26 stood at ₹78,729 crore and AUM stood at ₹2,10,704 crore as on December 31, 2025. In 9MFY26, of the total disbursements, vehicle finance (VF) contributed 56%, loan against property (LAP) 18%, new business 16%, gold loan 3% and home loans (HL) 7%. Of the total AUM of the company as on December 31, 2025, the share of VF was 53.6%, LAP was 23.3%, HL was 10.3%, micro, small and medium enterprise (MSME) was 4.0%, new business was 8.4%, and gold loan was at 0.5%.

In the VF segment, disbursements rose by 12% in FY25 to ₹53,922 crore (FY24: ₹48,348 crore), compared to a 22% growth in the previous year. Correspondingly, AUM in the VF segment increased by 26%, reaching ₹103,609 crore as on March 31, 2025, from ₹86,263 crore as on March 31, 2024. Within VF, disbursements for new and used vehicles grew by 11% and 13%, respectively. The company disbursed ₹43,991 crore in VF segment in 9MFY26.

Home equity segment recorded strong growth, with disbursements rising by 32% to ₹17,913 crore in FY25, up from ₹13,554 crore in FY24. Disbursements in the MSME segment moderated to ₹7,763 crore in FY25 from ₹8,106 crore in FY24, while the HL segment grew from ₹6,362 crore in FY24 to ₹7,404 crore in FY25. The disbursement in home equity segment, MSME and HL segment stood at ₹14,621 crore, ₹5,125 crore, and ₹5,468 crore, respectively, in 9MFY26.

Disbursement growth has slowed in SME loans considering exit from less profitable segments. In CSEL, there was moderation in growth considering exit from the Fintech-led lending model, prompted by rising delinquencies and regulatory changes, including the cap on first loss default guarantee (FLDG). New business segments accounted for 21% of total disbursements in FY25 and 13% of the AUM as on March 31, 2025.

Established track record in vehicle financing and experienced management team

Founded in 1978, CIFCL has a long-standing presence in the VF sector and has established a robust franchise across India. With 55% of its AUM allocated to VF, the company holds a prominent market position. CIFCL's VF portfolio is well-diversified, including cars and multi-utility vehicles (MUVs) at 34.4%, light commercial vehicles (LCVs) at 26.4%, heavy commercial vehicles (HCVs) at 13.7%, construction equipment (CE) at 8.6%, two and three-wheelers at 8.7%, tractors at 7.3%, and others at 0.9% as on

December 31, 2025. New vehicles constituted 72% of the outstanding VF portfolio, while used vehicles accounted for the remaining 28%, as on December 31, 2025. Having a diversified presence across the vehicle segment allows the company to sustain growth even in periods of reduced demand or asset quality issues in sub-segment. Despite increase in disbursements for new products, CareEdge Ratings expects the VF portfolio to remain a significant part of the company's assets.

The company's operations are handled by an experienced senior management team, many of whom have been with the group for over a decade. Vellayan Subbiah, CIFCL's Chairman, has 25 years of experience across fields, including consulting, technology, projects, and financial services. In FY24, Ravindra Kumar Kundu was appointed as Managing Director, bringing over three decades of experience in automobile and financial services industries. Arulselvan D, the company's Chief Financial Officer, has over 32 years of experience in finance and management including over 26 years of experience in the group. Most senior level management collectively have decades of experience in the company.

The board of directors, overseeing the company's performance, consists of eight members, including three from the Murugappa group and five independent directors.

Geographically diversified business operations

CIFCL's branch network has a pan-India presence and is diversified across 26 states and seven union territories (UTs), with 1,757 branches as on December 31, 2025, of which, 1,592 serve VF, 814 branches serve LAP, 710 branches serve HL, 504 branches serve CSEL, 414 branches serve SBPL, 116 branches serve SME loans and 118 branches serve gold loan. Of these, 805 LAP branches, 678 HL branches, 504 CSEL branches, 414 SBPL branches, and 116 SME branches are co-located with VF branches. Notably, 92% of CIFCL's branches are in Tier-III to Tier-VI towns, reflecting the company's deep rural and semi-urban reach. Regionally, the branch distribution is well-balanced, with 33% in the south, 25% in the east, 22% in the north, and 20% in the west. As on December 31, 2025, rural branches accounted for 82% of the total network, while semi-urban branches represented 10% and urban branches represented 8%.

Diversified funding profile

CIFCL maintains a well-diversified funding profile, with access to a mix of bank borrowings and market instruments such as non-convertible debentures (NCDs), subordinated debt, and commercial paper (CP). As on March 31, 2025, term loans constituted 44% of the company's total borrowings (previous year: 46%), followed by securitisation at 15% (PY: 18%), debentures at 14% (PY: 15%), borrowings from international financial institutions (IFI) at 7% (PY: 7%), Tier-II capital at 6% (PY: 4%), External Commercial Bonds (ECB) borrowings at 8% (PY: 4%), cash credit/working capital demand loans (CC/WCDL) and short-term loans (STL) at 3% (PY: 3%), CP at 2% (PY: 2%), and compulsorily convertible debentures (CCD) at 1% (PY: 2%). As on December 31, 2025, the funding mix remained broadly stable, with term loans at 43%, debentures at 13%, securitisation at 15%, IFI at 6%, Tier-II capital at 6%, ECB at 7%, CC/WCDL and STL at 3%, CP at 6%, and CCD at 1%.

Healthy profitability

CIFCL reported a PAT of ₹4,259 crore in FY25, marking a 24% y-o-y growth from ₹3,423 crore in FY24, on a total income of ₹26,055 crore (PY: ₹19,216 crore). Improvement in net interest margin (NIM) in FY25 was driven by a reduction in the cost of borrowings, while operating expenses (Opex) as a percentage of total assets remained stable compared to the previous year. Pre-provision operating profit (PPOP) rose significantly from ₹5,904 crore in FY24 to ₹8,231 crore in FY25. However, overall credit cost as a percentage of total assets increased to 1.40% in FY25 (PY: 0.98%), primarily due to higher delinquency levels in the VF portfolio. ROTA stood at 2.39% in FY25, slightly lower than 2.55% in FY24.

In 9MFY26, the company reported a PAT of ₹3,579 crore and a PPOP of ₹7,513 crore compared to PAT of ₹2,992 crore and a PPOP of ₹5,900 crore in 9MFY25. NIM and Opex remained stable in 9MFY26, although ROTA declined marginally due to elevated credit costs. CareEdge Ratings expects CIFCL's profitability to remain healthy over the medium term.

Capitalisation levels

As on March 31, 2025, CIFCL reported a capital adequacy ratio (CAR) of 19.75% and Tier-I CAR of 14.41%, compared to 18.56% and 15.09%, respectively, as on March 31, 2024. Improvement was primarily driven by strong internal accruals. Overall gearing increased to 7.7x as on March 31, 2025 (PY: 7.1x) and stood at 7.5x as on December 31, 2025. Adjusted gearing, considering compulsorily convertible debentures (CCD) as part of equity, stood at 7.0x as on March 31, 2025, and 7.0x as on December 31, 2025. As on December 31, 2025, CAR and Tier-I CAR further improved to 19.16% and 14.21%, respectively. CareEdge Ratings expects CIFCL to maintain a capital cushion of at least 2% above the regulatory requirement. The company has demonstrated a consistent track record of equity capital raising, having mobilised ₹250 crore in FY11, ₹212 crore in FY12, ₹300 crore in FY13,

₹500 crore in FY15, ₹1,200 crore in FY20, and ₹4,000 crore in FY24 from investors, including promoters. Going forward, the company's ability to sustain gearing levels in line with industry peers will be critical.

Key weaknesses

Moderate asset quality

As on March 31, 2025, CIFCL's Gross Stage 3 and Net Stage 3 assets moderated to 2.81% and 1.54%, respectively, compared to 2.48% and 1.33% as on March 31, 2024. Under the Income Recognition, Asset Classification and Provisioning (IRACP) norms, GNPA and net NPAs (NNPAs) stood at 3.97% and 2.63%, respectively, as on March 31, 2025. Moderation in asset quality was primarily driven by increased delinquencies in the VF segment, impacted by a weak rural economy and lower vehicle utilisation due to heat waves, excessive rainfall, and election-related disruptions in H1FY25. Although utilisation improved to 70–80% by Q3/Q4, it remained below the previous year's peak of 90%. Recovery in asset quality has been slow, as customers already in Stage 3 face challenges in regularising accounts due to the burden of multiple overdue equated monthly installments (EMIs).

New business segments such as CSEL, SBPL, and MSME lending also experienced elevated delinquencies. In CSEL, the stress was largely attributed to partnership and fintech-originated loans, exacerbated by regulatory changes such as FLDG cap. The company is gradually running down the riskier partnership book and expects asset quality to improve as these exposures reduce and as seasonality in these products normalises.

As on December 31, 2025, CIFCL's Gross Stage 3 and Net Stage 3 assets stood at 3.36% and 1.91%, respectively, while GNPA and NNPA under IRACP norms were at 4.63% and 3.13%. Rise in NPA levels in 9MFY26 was primarily driven by the early arrival of monsoon, which disrupted vehicle movement and led to reduced utilisation. A slowdown in industrial production impacted borrower income, particularly in the VF segment. CareEdge Ratings expects asset quality to remain broadly stable in the medium term. The company's ability to improve asset quality while continuing to grow its portfolio will remain a key monitorable.

Liquidity: Strong

The company's asset and liability management (ALM) as on December 31, 2025, indicated no cumulative mismatches up to the one-year bucket. The company's liquidity position, comprising cash and bank balances and undrawn sanctioned bank lines, stood at ₹21,808 crore as on December 31, 2025. CIFCL benefits from well-established banking relationships, and its liquidity profile is further strengthened by its strong parentage as part of the Murugappa Group.

Environment, social, and governance (ESG) risks

Although CIFCL's service-oriented business model limits its direct exposure to environmental risks, credit risk may arise if operations of asset class of the portfolio are adversely impacted by environmental factors. The company will proactively develop and introduce innovative financing solutions to support these eco-friendly technologies, ensuring that customers have access to the latest sustainable options.

Social risks in the form of cybersecurity threat or customer data breach or mis-selling practices can affect CIFCL's regulatory compliance and reputation, and hence, remain a key monitorable. The company continues to implement a range of impactful CSR initiatives across the nation, focusing on areas vital for societal progress, such as education, health, and livelihood creation.

CIFCL's Board comprises eight Directors, with five Independent Directors and one female Directors. The company has policies and processes in place to enable highest standards in governance and transparency, ethical behaviour, and board diversity, among others.

Applicable criteria

[Definition of Default](#)

[Rating Outlook and Rating Watch](#)

[Financial Ratios - Financial Sector](#)

[Short Term Instruments](#)

[Non Banking Financial Companies](#)

About the company and industry

Industry classification

Macroeconomic indicator	Sector	Industry	Basic industry
Financial Services	Financial Services	Finance	Non-Banking Financial Company (NBFC)

CIFCL is a non-banking financial company (NBFC) having a track record of over four decades, promoted by the Chennai-based Murugappa group. As on December 31, 2025, the group holds 49.72% stake in CIFCL. The company has major presence in the VF and HE (home equity; LAP) segment. The company has 1,757 branches as on December 31, 2025, spread across 26 states, and seven UTs across India with a business AUM of ₹2,10,704 crore, of which, the share of VF was 53.6%, LAP was 23.3%, HL was 10.3%, MSME was 4.0%, new business was 8.4% and gold loan at 0.5%.

Brief Financials (₹ crore)	31-03-2024	31-03-2025	31-12-2025
Standalone	A	A	UA
Total income	19,216	26,055	22,906
Profit after tax (PAT)	3,423	4,259	3,579
Assets under management (AUM)	148,167	184,746	210,704
On-book gearing (x)	7.14	7.76	7.50
AUM / tangible net-worth (TNW) (x)	7.85	8.34	8.15
Gross non-performing assets (NPA) / gross stage 3 (%)*	2.48/3.54*	2.81/3.97*	3.36/4.63*
Return on managed assets (ROMA) (%)	2.52	2.38	2.20
Capital adequacy ratio (CAR) (%)	18.56	19.75	19.16

A: Audited UA: Unaudited; Note: these are latest available financial results

*Per IRACP norms

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for last three years: Annexure-2

Detailed explanation of covenants of rated instrument / facility: Annexure-3

Complexity level of instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned and Rating Outlook
Debentures-Non-convertible debentures-I	Proposed	-	-	-	395.00	CARE AA+; Stable
Debentures-Non-convertible debentures-I	INE121A07QU7	12-12-2022	8.30%	12-12-2025	605.00	CARE AA+; Stable
Debentures-Non-convertible debentures-II	INE121A07SO6	14-10-2025	7.58%	14-10-2030	550.00	CARE AA+; Stable
Debentures-Non-convertible debentures-II	INE121A07SQ1	20-01-2026	7.73%	20-01-2031	400.00	CARE AA+; Stable
Debentures-Non-convertible debentures-II	Proposed	-	-	-	9050.00	CARE AA+; Stable
Debt-Subordinate debt-IV	INE121A08OH7	23-08-2018	9.75%	23-08-2028	300.00	CARE AA+; Stable
Debt-Subordinate debt-V	INE121A08OG9	05-04-2018	9.05%	24-03-2028	530.00	CARE AA+; Stable
Debt-Subordinate debt-V	Proposed	-	-	-	170.00	CARE AA+; Stable
Debt-Perpetual Debt	Proposed	-	-	-	300.00	CARE AA; Stable
Debt-Subordinate Debt - VI	INE121A08PX1	25-11-2025	8.40%	25-11-2032	500.00	CARE AA+; Stable
Debt-Subordinate Debt - VI	Proposed	-	-	-	1000.00	CARE AA+; Stable
Debt-Subordinate Debt - VII	Proposed	-	-	-	2000.00	CARE AA+; Stable
Commercial Paper-Commercial Paper (Standalone)	INE121A14YA9	26-11-2025	6.60%	25-02-2026	500.00	CARE A1+
Commercial Paper-Commercial Paper (Standalone)	INE121A14YB7	28-11-2025	7.15%	27-11-2026	500.00	CARE A1+
Commercial Paper-Commercial Paper (Standalone)	INE121A14YD3	19-12-2025	6.73%	27-02-2026	500.00	CARE A1+
Commercial Paper-Commercial	INE121A14YC5	19-12-2025	6.68%	20-03-2026	500.00	CARE A1+

Paper (Standalone)						
Commercial Paper-Commercial Paper (Standalone)	INE121A14YE1	22-12-2025	6.67%	23-03-2026	750.00	CARE A1+
Commercial Paper-Commercial Paper (Standalone)	INE121A14YF8	23-01-2026	7.74%	22-01-2027	1000.00	CARE A1+
Commercial Paper-Commercial Paper (Standalone)	INE121A14YG6	27-01-2026	7.70%	25-01-2027	500.00	CARE A1+
Commercial Paper-Commercial Paper (Standalone)	INE121A14YH4	27-01-2026	7.70%	25-11-2026	555.00	CARE A1+
Commercial Paper-Commercial Paper (Standalone)	INE121A14YI2	05-02-2026	7.65%	04-02-2027	1000.00	CARE A1+
Commercial Paper-Commercial Paper (Standalone)	INE121A14YJ0	05-02-2026	7.63%	03-08-2026	375.00	CARE A1+
Commercial Paper-Commercial Paper (Standalone)	INE121A14YK8	12-02-2026	7.59%	11-02-2027	420.00	CARE A1+
Commercial Paper-Commercial Paper (Standalone)	INE121A14YL6	16-02-2026	7.59%	15-02-2027	1000.00	CARE A1+
Commercial Paper-Commercial Paper (Standalone)	Proposed	-	-	-	17,400.00	CARE A1+

Annexure-2: Rating history for last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2025-2026	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022-2023
1	Bonds-Perpetual Bonds	LT	-	-	-	-	-	1)Withdrawn (05-Jul-22)
2	Debt-Perpetual Debt	LT	-	-	-	-	1)Withdrawn (08-Dec-23)	1)CARE AA; Stable (09-Dec-22)

								2)CARE AA; Stable (05-Jul-22)
3	Debt-Subordinate Debt	LT	-	-	-	-	-	1)Withdrawn (09-Dec-22) 2)CARE AA+; Stable (05-Jul-22)
4	Debt-Perpetual Debt	LT	-	-	-	-	1)Withdrawn (08-Dec-23)	1)CARE AA; Stable (09-Dec-22) 2)CARE AA; Stable (05-Jul-22)
5	Debt-Perpetual Debt	LT	-	-	1)Withdrawn (02-Apr-25)	1)CARE AA; Stable (27-Jun-24)	1)CARE AA; Stable (08-Dec-23)	1)CARE AA; Stable (09-Dec-22) 2)CARE AA; Stable (05-Jul-22)
6	Debt-Subordinate Debt	LT	-	-	-	1)Withdrawn (27-Jun-24)	1)CARE AA+; Stable (08-Dec-23)	1)CARE AA+; Stable (09-Dec-22) 2)CARE AA+; Stable (05-Jul-22)
7	Debt-Perpetual Debt	LT	-	-	-	-	1)Withdrawn (08-Dec-23)	1)CARE AA; Stable (09-Dec-22) 2)CARE AA; Stable (05-Jul-22)
8	Debt-Perpetual Debt	LT	-	-	1)Withdrawn (02-Apr-25)	1)CARE AA; Stable (27-Jun-24)	1)CARE AA; Stable (08-Dec-23)	1)CARE AA; Stable (09-Dec-22) 2)CARE AA; Stable (05-Jul-22)
9	Debt-Subordinate Debt	LT	-	-	-	1)Withdrawn (27-Jun-24)	1)CARE AA+; Stable (08-Dec-23)	1)CARE AA+; Stable (09-Dec-22) 2)CARE AA+; Stable (05-Jul-22)
10	Debt-Perpetual Debt	LT	-	-	1)Withdrawn (02-Apr-25)	1)CARE AA; Stable (27-Jun-24)	1)CARE AA; Stable (08-Dec-23)	1)CARE AA; Stable (09-Dec-22)

								2)CARE AA; Stable (05-Jul-22)
11	Debt-Subordinate Debt	LT	300.00	CARE AA+; Stable	1)CARE AA+; Stable (21-Nov-25) 2)CARE AA+; Stable (09-Oct-25) 3)CARE AA+; Stable (06-Oct-25) 4)CARE AA+; Stable (02-Apr-25)	1)CARE AA+; Stable (27-Jun-24)	1)CARE AA+; Stable (08-Dec-23)	1)CARE AA+; Stable (09-Dec-22) 2)CARE AA+; Stable (05-Jul-22)
12	Debt-Subordinate Debt	LT	700.00	CARE AA+; Stable	1)CARE AA+; Stable (21-Nov-25) 2)CARE AA+; Stable (09-Oct-25) 3)CARE AA+; Stable (06-Oct-25) 4)CARE AA+; Stable (02-Apr-25)	1)CARE AA+; Stable (27-Jun-24)	1)CARE AA+; Stable (08-Dec-23)	1)CARE AA+; Stable (09-Dec-22) 2)CARE AA+; Stable (05-Jul-22)
13	Debentures-Non-convertible debentures	LT	1000.00	CARE AA+; Stable	1)CARE AA+; Stable (21-Nov-25) 2)CARE AA+; Stable (09-Oct-25) 3)CARE AA+; Stable (06-Oct-25) 4)CARE AA+; Stable (02-Apr-25)	1)CARE AA+; Stable (27-Jun-24)	1)CARE AA+; Stable (08-Dec-23)	1)CARE AA+; Stable (09-Dec-22)
14	Debentures-Non-convertible debentures	LT	10000.00	CARE AA+; Stable	1)CARE AA+; Stable (21-Nov-25) 2)CARE AA+; Stable (09-Oct-25)	1)CARE AA+; Stable (27-Jun-24)	-	-

					3)CARE AA+; Stable (06-Oct-25)			
					4)CARE AA+; Stable (02-Apr-25)			
15	Commercial Paper-Commercial Paper (Standalone)	ST	25000.00	CARE A1+	1)CARE A1+ (21-Nov-25) 2)CARE A1+ (09-Oct-25) 3)CARE A1+ (06-Oct-25)	-	-	-
16	Debt-Subordinate Debt	LT	1500.00	CARE AA+; Stable	1)CARE AA+; Stable (21-Nov-25)	-	-	-
17	Debt-Perpetual Debt	LT	300.00	CARE AA; Stable	1)CARE AA; Stable (21-Nov-25)	-	-	-
18	Debt-Subordinate Debt	LT	2000.00	CARE AA+; Stable				

LT: Long term; ST: Short term

Annexure-3: Detailed explanation of covenants of rated instruments/facilities: Not applicable

Annexure-4: Complexity level of instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Commercial Paper-Commercial Paper (Standalone)	Simple
2	Debentures-Non-convertible debentures	Simple
3	Debt-Perpetual Debt	Complex
4	Debt-Subordinate Debt	Simple

Annexure-5: Lender details

To view lender-wise details of bank facilities please [click here](#)

Note on complexity levels of rated instruments: CareEdge Ratings has classified instruments rated by it based on complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for clarifications.

Contact us

<p>Media Contact</p> <p>Mradul Mishra Director CARE Ratings Limited Phone: +91-22-6754 3596 E-mail: mradul.mishra@careedge.in</p> <p>Relationship Contact</p> <p>Pradeep Kumar V Senior Director CARE Ratings Limited Phone: 044-2850 1001 E-mail: pradeep.kumar@careedge.in</p>	<p>Analytical Contacts</p> <p>Sanjay Agarwal Senior Director CARE Ratings Limited Phone: +91-22-6754 3500 E-mail: Sanjay.Agarwal@careedge.in</p> <p>Vineet Jain Senior Director CARE Ratings Limited Phone: +91-22-6754 3623 E-mail: vineet.jain@careedge.in</p> <p>Akansha Akshay Jain Assistant Director CARE Ratings Limited Phone: +91-22-6754 3491 E-mail: akansha.jain@careedge.in</p>
--	---

About us:

Established in 1993, CareEdge Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the Reserve Bank of India. With an equitable position in the Indian capital market, CareEdge Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CareEdge Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CareEdge Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit. For more information: www.careratings.com

Disclaimer:

This disclaimer pertains to the ratings issued and content published by CARE Ratings Limited ("CareEdge Ratings"). Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. Any opinions expressed herein are in good faith and are subject to change without notice. The rating reflects the opinions as on the date of the rating. A rating does not convey suitability or price for the investor. The rating agency does not conduct an audit on the rated entity or an independent verification of any information it receives and/or relies on for the rating exercise. CareEdge Ratings has based its ratings/outlook on the information obtained from reliable and credible sources. CareEdge Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. The users of the rating should rely on their own judgment and may take professional advice while using the rating in any way. CareEdge Ratings shall not be liable for any losses that user may incur or any financial liability whatsoever to the user of the rating. The use or access of the rating does not create a client relationship between CareEdge Ratings and the user.

CAREEDGE RATINGS DISCLAIMS WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR OTHER WARRANTIES OR CONDITIONS, TO THE EXTENT PERMITTED BY APPLICABLE LAWS, INCLUDING WARRANTIES OF MERCHANTABILITY, ACCURACY, COMPLETENESS, ERROR-FREE, NON-INFRINGEMENT, NON-INTERRUPTION, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE OR INTENDED USAGE.

Most entities whose bank facilities/instruments are rated by CareEdge Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CareEdge Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. CareEdge Ratings does not act as a fiduciary by providing the rating. The ratings are intended for use only within the jurisdiction of India. The ratings of CareEdge Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades. CareEdge Ratings has established policies and procedures as required under applicable laws and regulations which are available on its website.

Privacy Policy applies. For Privacy Policy please refer to https://www.careratings.com/privacy_policy

© 2026, CARE Ratings Limited. All Rights Reserved.

This content is being published for the purpose of dissemination of information required as per applicable law and regulations and CARE Ratings Limited holds exclusive copyright over the same. Any reproduction, retransmission, modification, derivative works or use or reference to the contents, in whole, in part or in any form, is prohibited except with prior express written consent from CARE Ratings Limited.

**For detailed Rating Report and subscription information,
please visit www.careratings.com**